Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Donepezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 8/20 | 1.00 |
| ▸ | BCHE | P06276 | 8/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Donepezil SCHEMBL2149 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3851203 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL3516 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL12043710 | 1.00 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL4979379 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL356844 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1559622 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL1815 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL17352708 | 0.99 | BCHE (0.98) | BCHEACHEFAAHABCC4CACNA1F | |
| Donepezil SCHEMBL5060933 | 0.99 | BCHE (1.00) | BCHEACHEFAAHABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 878 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3733168-B1 | TRANSDERMAL ABSORPTION AGENT COMPRISING DONEPEZIL FOR TREATMENT OF DEMENTIA | DONG A ST CO LTD (KR) | 2026-05-27 | — | — | EP | claimed |
| US-20250375396-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | CORIUM LLC (US) | 2025-12-11 | — | — | US | claimed |
| US-20250325496-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | CORIUM LLC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250195415-A1 | BIODEGRADABLE CONTROLLED RELEASE ANTIVIRAL AGENT IMPLANTS | UNIV YALE (US) | 2025-06-19 | — | — | US | claimed |
| WO-2025073915-A1 | TREATMENT OF LEUKODYSTROPHY | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2025-04-10 | — | — | WO | claimed |
| EP-4534086-A1 | TREATMENT OF LEUKODYSTROPHY | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) | 2025-04-09 | — | — | EP | claimed |
| CN-117143044-B | Fluorescent probe for hydrazine detection and preparation method and application thereof | 新乡医学院 | 2025-01-17 | — | — | CN | claimed |
| EP-4473964-A1 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | Dr.Noah Biotech Inc. (KR) | 2024-12-11 | — | — | EP | claimed |
| US-20240343859-A1 | POLY(ETHYLENE BRASSYLATE-CO-DIOXANONE) COPOLYMERS, METHOD OF SYNTHESIS AND BIOMEDICAL DEVICES MADE THEREFROM | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2024-10-17 | — | — | US | claimed |
| CN-118647376-A | Compositions comprising a beta blocker and a cholinesterase inhibitor for the treatment of neurodegenerative diseases | 诺亚博士生物科技有限公司 | 2024-09-13 | — | — | CN | claimed |
| WO-2022204519-A1 | USE OF ZT-1A AND ANALOGS THEREOF TO PREVENT AND/OR TREAT NEURODEGENERATIVE AND NEUROCOGNITIVE DISORDERS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-09-29 | — | — | WO | claimed |
| CN-114672020-A | Preparation method of benzoxazine-based conjugated trapezoidal polymer and application of benzoxazine-based conjugated trapezoidal polymer in hydrogen sulfide detection | 天津科技大学 | 2022-06-28 | — | — | CN | claimed |
| US-20220062195-A1 | CURCUPHENOL COMPOUNDS FOR INCREASING MHC-I EXPRESSION | Cava Healthcare Inc. (CA) | 2022-03-03 | — | — | US | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265524-A | Compositions containing mixtures of indene or indane derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| EP-2098232-B1 | PERCUTANEOUS ABSORPTION PREPARATION | NITTO DENKO CORP (JP) | 2013-06-05 | — | — | EP | claimed |
| EP-2478099-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA | Chase Pharmaceuticals Corporation (US) | 2012-07-25 | — | — | EP | claimed |
| CN-1753675-A | Therapeutic articles for treating beta amyloid related diseases | NEUROCHEM INTERNAT LTD (CH) | 2006-03-29 | — | — | CN | claimed |
| CN-1709508-A | Use of acetylcholinesterase inhibitor for preparing diabetes medicines | SHANGHAI SAIDA BIOTECHNOLOGY R (CN) | 2005-12-21 | — | — | CN | claimed |
| CN-1640399-A | Use of acetylchloinesterase inhibitor for preparing medicine for treating parkinson's disease | SAIDA BIOLOG TECHNOLOGY RES CT (CN) | 2005-07-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195415-A1 | BIODEGRADABLE CONTROLLED RELEASE ANTIVIRAL AGENT IMPLANTS | PRUNE1, ALOX15, LTA | ACHE 2911/4885BCHE 662/4885FAAH 1233/4885 |
| US-20220062195-A1 | CURCUPHENOL COMPOUNDS FOR INCREASING MHC-I EXPRESSION | CD74, MICA, HLA-DRB1 | ACHE 3240/4885BCHE 3538/4885FAAH 2480/4885 |
| US-20250375396-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | SLC10A2, SLC10A1, ABCB11 | ACHE 1484/4885BCHE 226/4885FAAH 462/4885 |
| US-20250325496-A1 | SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUG | SLC10A2, SLC10A1, ABCB11 | ACHE 1484/4885BCHE 226/4885FAAH 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.